Maternal Odor as a Developmental Care Intervention for Apnea of Prematurity
NCT07689669
Apnea, Apnea of Prematurity
Konya, Turkey (Türkiye)
View Trial DetailsNCT Number: NCT03061890
The DINE study will test the hypothesis that potentially avoidable NICU-based exposures contribute to the neuro-cognitive and somatic impairments prevalent among NICU graduates. This hypothesis is drawn from the documented impact of phthalate exposure on early development in term-born children, and the acknowledged presence of these toxic chemicals in the NICU. Third trimester in utero exposure to phthalates have been linked to poorer childhood performance in cognition, motor function, attention, hyperactivity and social behavior. Phthalate exposure is also associated with altered onset of puberty and asthma. The multi-site cohort and approach will clarify the role of NICU-based phthalate exposure on high-prevalence clinical outcomes.
Looking for future studies?
Notify MeUp to 12 year
All sexes
Observational
University of Florida, Jacksonville, Florida, United States
Background: Each year in the United States, over 300,000 preterm infants are admitted to neonatal intensive care units (NICUs) where they are exposed to a chemical-intensive hospital environment during a developmentally vulnerable period. Many life-saving and supportive respiratory, nutritional, hematologic and pharmaceutical therapies in the NICU expose preterm infants to potentially harmful chemicals during a life stage analogous to the third trimester of gestation. The NIH-funded DINE study capitalizes on the infrastructure, biorepositories, and extensive clinical databases of four existing preterm cohorts to explore the hypothesis that early life exposure to phthalates adversely impacts neurodevelopment, lung function, growth, adiposity, and pubertal development in childhood.
The scientific premise of the DINE study is that early life exposure to phthalates, a class of chemical plasticizers ubiquitous in the NICU, has long-lasting harmful effects on child health and development, and that these harmful effects are magnified in children born preterm. This premise is based on strong evidence of multisystem adverse health effects in term-born children who are exposed to phthalates in utero during the third trimester of pregnancy or in early infancy. In preterm infants, however, rigorously obtained data on the health effects of phthalates are scant. Dermal, inhalational and intravenous exposures to phthalates are widespread in some NICUs, where preterm infants are cared for during the sensitive "third trimester" developmental window. Moreover, premature infants experience a high prevalence of the adverse health effects that are associated with early life exposures to phthalates in term-born children, including altered neurodevelopment, poor pulmonary function, and maladapted growth. A rigorous, well-designed, sufficiently powered study of NICU-based phthalate exposures and long-term health outcomes of preterm infants has the potential to change care practices, promote regulatory policy changes and lead to mitigation of phthalate exposures in the NICU.
Significance: The proposed research is expected to identify modifiable sources of developmental risk for NICU patients that can inform and improve hospital care and long-term outcome. Moreover, our findings could lead to relatively inexpensive NICU interventions, such as use of non-phthalate containing medical materials, dosing guidelines for elemental metals and guidance for parents and staff on infant stress-reduction, and policy changes (e.g. regulation of the phthalates used in medical devices or changes to the trace metal content of parenteral nutrition) with significant positive potential impacts on life-long morbidities common among NICU graduates. Information gleaned from studying our highly-exposed, highly-vulnerable population may elucidate health impacts of early life exposures that translate to risk reduction in the general population.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: One time between the ages of 3 to 4
Brief Respiratory Questionnaire to determine association between exposure and lung health
Time frame: One time between the ages of 5 to 6
PROMIS® (Patient-Reported Outcomes Measurement Information System) Parent Proxy Asthma Impact item bank to determine association between exposure and asthma
Time frame: Twice between the ages of 8 to 12
PhenX (consensus measures for Phenotypes and eXposures) Toolkit measures of spirometry and bronchodilator responsiveness to determine association between exposure and asthma
Time frame: Twice between the ages of 8 to 12
PROMIS Pediatric Asthma Impact item bank to determine the association between exposures and asthma
Time frame: Twice within 24 months between the ages of 3 to 5
NIH Toolbox Early Childhood Cognition Battery to determine the associations between exposures and neurocognitive behavioral development
Time frame: Twice within 24 months between the ages of 7 to 9
NIH Toolbox Cognition Battery to determine the associations between exposures and neurocognitive behavioral development
Time frame: Twice within 24 months between the ages of 4 to 6
NIH Toolbox Early Childhood Motor Battery to determine the associations between exposures and neurocognitive behavioral development
Time frame: Twice between the ages of 8 to 12
NIH Toolbox Motor Battery to determine the associations between exposures and neurocognitive behavioral development
Time frame: One time between the ages of 3 to 4
Child Behavior Checklist (CBCL) to determine the associations between exposures and neurocognitive behavioral development
Time frame: Three times between the ages of 5 to 12
PROMIS Cognitive Item bank to determine the associations between exposures and neurocognitive behavioral development
Time frame: Three times between the ages of 5 to 12
PROMIS Pediatric Mobility Item bank to determine the associations between exposures and neurocognitive behavioral development
Time frame: Three times between the ages of 5 to 12
PROMIS Pediatric Upper Extremity Item to determine the associations between exposures and neurocognitive behavioral development
Time frame: Annually, up to 12 years
Measurement of height, weight, head circumference, mid-upper arm circumference and bioimpedence scale to determine associations between exposures and heathy growth and obesity
Time frame: Annually, up to 12 years
Parent reported height and weight to determine associations between exposures and healthy growth and obesity
Time frame: Annually, up to 12 years
PhenX Assessment of Pubertal Development to determine associations between exposures and pubertal development
Albert Einstein College of Medicine
Other
Developmental Impact of Neonatal Intensive Care Unit (NICU) Exposures: Environmental Influences on Child Health Outcomes (ECHO)
Acronym: DINE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689669
Apnea, Apnea of Prematurity
Konya, Turkey (Türkiye)
View Trial DetailsNCT07622459
Female Urogenital Diseases and Pregnancy Complications, Mechanical Ventilation
Sanliurfa, Turkey (Türkiye)
View Trial DetailsNCT07577180
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia (BPD)
Köseköy, Kocaeli, Turkey (Türkiye)
View Trial DetailsNCT07494123
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cairo, Cairo Governorate, Egypt
View Trial Details